Page 1,644«..1020..1,6431,6441,6451,646..1,6501,660..»

Stem cell research Experts@Minnesota

Posted: October 18, 2016 at 4:43 pm

TY - CHAP

T1 - Stem cell research

AU - Norrander,Barbara

AU - Norrander,Jan

PY - 2007

Y1 - 2007

N2 -

At the 2004 Democratic convention, Ron Reagan, the son of the former president, took the podium to call for increased federal funding for stem cell research. Nancy Reagan also publicly supported stem cell research in the hope that some day this research could help to cure the Alzheimer's disease that had stricken her husband. Meanwhile in California, Republican governor Arnold Schwarzenegger supported Proposition 71, which would provide $3 billion in state aid for stem cell research. Yet despite support from some prominent Republicans, President George W. Bush generally opposed stem cell research due to ethical concerns over the destruction of human embryos. In August 2001 he had limited federal funding for such research to the existing sixty cell lines. In contrast, Democratic presidential nominee John Kerry promised a fourfold increase in federal funding. The question remained whether stem cell research would become a decisive issue in the 2004 election. Various reasons existed to suspect that it would not. Voters were probably less aware of this issue than of more long-standing or common issues, such as the state of the economy. Voters also were receiving mixed signals as to the partisan content of the issue. On the one hand, voters' opinions on the stem cell issue might overlap with other moral issues, such as abortion, causing stem cell opinions to supplement, but not change, existing patterns of political preferences. On the other hand, stem cell research was a debated topic during the campaign, and positions on the issue might not line up directly with attitudes on other moral issues. In investigating these questions, the chapter proceeds as follows. We begin with a brief overview of the science behind stem cell research and then turn to an analysis of whether opinions on stem cells had any impact on the 2004 presidential vote. We conclude with a discussion of whether stem cell research is likely to become the "new abortion"-a long-standing issue that divides the parties. 2007 Royal Institute of International Affairs.

AB -

At the 2004 Democratic convention, Ron Reagan, the son of the former president, took the podium to call for increased federal funding for stem cell research. Nancy Reagan also publicly supported stem cell research in the hope that some day this research could help to cure the Alzheimer's disease that had stricken her husband. Meanwhile in California, Republican governor Arnold Schwarzenegger supported Proposition 71, which would provide $3 billion in state aid for stem cell research. Yet despite support from some prominent Republicans, President George W. Bush generally opposed stem cell research due to ethical concerns over the destruction of human embryos. In August 2001 he had limited federal funding for such research to the existing sixty cell lines. In contrast, Democratic presidential nominee John Kerry promised a fourfold increase in federal funding. The question remained whether stem cell research would become a decisive issue in the 2004 election. Various reasons existed to suspect that it would not. Voters were probably less aware of this issue than of more long-standing or common issues, such as the state of the economy. Voters also were receiving mixed signals as to the partisan content of the issue. On the one hand, voters' opinions on the stem cell issue might overlap with other moral issues, such as abortion, causing stem cell opinions to supplement, but not change, existing patterns of political preferences. On the other hand, stem cell research was a debated topic during the campaign, and positions on the issue might not line up directly with attitudes on other moral issues. In investigating these questions, the chapter proceeds as follows. We begin with a brief overview of the science behind stem cell research and then turn to an analysis of whether opinions on stem cells had any impact on the 2004 presidential vote. We conclude with a discussion of whether stem cell research is likely to become the "new abortion"-a long-standing issue that divides the parties. 2007 Royal Institute of International Affairs.

UR - http://www.scopus.com/inward/record.url?scp=84901178893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901178893&partnerID=8YFLogxK

M3 - Chapter

SN - 0815710178

SN - 9780815713272

SP - 142

EP - 159

BT - A Matter of Faith: Religion in the 2004 Presidential Election

PB - Brookings Institution Press

ER -

Read more:
Stem cell research Experts@Minnesota

Posted in Minnesota Stem Cells | Comments Off on Stem cell research Experts@Minnesota

Worlds Leading Immunology Congress | Conferenceseries

Posted: October 18, 2016 at 4:40 pm

Accreditation Statement

This activity (World Immunology Summit 2016) has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and Conference Series, LLC. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

PeerPoint Medical Education Institute designates the live format for this educational activity for AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Conference series invites participants from all over the world to attend "6th International Conference and Exhibition on Immunology" October 24-26, 2016 Chicago, USA includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Presenters can availupto 20 CME credits..

The annual International Conference on Immunology offer a unique platform for academia, Societies and Industries interested in immunology and Biomedical sciences to share the latest trends and important issues in the field. Immunology Summit-2016 brings together the Global leaders in Immunology and relevant fields to present their research at this exclusive scientific program. The Immunology Conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology. Immunology Summit 2016 Organizing Committee also intended to encourage Young investigators at every career stage to submit abstracts reporting their latest scientific findings in oral and poster sessions.

Track 1:ClinicalImmunology: Current & Future Research

Immunology is the study of the immune system. The immune system is how all animals, including humans, protect themselves against diseases. The study of diseases caused by disorders of the immune system is clinical immunology. The disorders of the immune system fall into two broad categories:

Immunodeficiency, in this immune system fails to provide an adequate response.

Autoimmunity, in this immune system attacks its own host's body.

Related:Immunology Conferences|Immunologists Meetings|Conference Series LLC

2nd International Conference on Antibodies and Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA;5th European Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th International Conference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd international conference on innate immunity, July 21-22, 2016, Germany; International Conference on Autoimmunity, October 13-14, 2016 Manchester, UK; Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA;USA Immunology Conferences;InternationalConference onMucosalImmunology, July 28-29, 2016, Australia;International Congress of Immunology

Track 2:Cancer and Tumor Immunobiology

The immune system is the bodys first line of defence against most diseases and unnatural invaders.Cancer Immunobiologyis a branch ofimmunologyand it studies interactions between theimmune systemandcancer cells. These cancer cells, through subtle alterations, become immortal malignant cells but are often not changed enough to elicit an immune reaction.Understanding how the immune system worksor does not workagainst cancer is a primary focus of Cancer Immunology investigators. Certain cells of the immune system, including natural killer cells, dendritic cells (DCs) and effector T cells, are capable of driving potent anti-tumour responses.

Tumor Immunobiology

The immune system can promote the elimination of tumours, but often immune responses are modulated or suppressed by the tumour microenvironment. The Tumour microenvironment is an important aspect of cancer biology that contributes to tumour initiation, tumour progression and responses to therapy. Cells and molecules of the immune system are a fundamental component of the tumour microenvironment. Importantly, therapeutic strategies can harness the immune system to specifically target tumour cells and this is particularly appealing owing to the possibility of inducing tumour-specific immunological memory, which might cause long-lasting regression and prevent relapse in cancer patients. The composition and characteristics of the tumour micro environment vary widely and are important in determining the anti-tumour immune response. Tumour cells often induce an immunosuppressive microenvironment, which favours the development of immuno suppressive populations of immune cells, such as myeloid-derived suppressor cells and regulatory T cells.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

2nd International Conference and Exhibition on Antibodies and Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; International Conference on Tumor Immunology and Immunotherapy, July 28-30, 2016 Melbourne, Australia; International Conference on Cancer Immunology and Immunotherapy, July 28-30, 2016 Melbourne, Australia, 2nd international congress on Neuroimmunology & therapeutics, Dec 01-03, 2016, USA; 2nd international conference on innate immunity, July 21-22, 2016, Germany;Immunology events;9th EuropeanMucosal ImmunologyMeetings, October 9 - 12 October, Scotland; international congress on immunology, august 21-26, 2016, Australia; 4th European Immunology events September 6-9, 2015, Austria

Track 3:Inflammation and Therapies

Inflammation is the body's attempt at self-protection; the aim being to remove harmful stimuli, including damaged cells, irritants, or pathogens - and begin the healing process. In Inflammation the body's whiteblood cellsand substances they produce protect us from infection with foreign organisms, such as bacteria and viruses. However, in some diseases, likearthritis, the body's defense system, the immune system triggers an inflammatory response when there are no foreign invaders to fight off. In these diseases, called autoimmune diseases, the body's normally protective immune system causes damage to its own tissues. The body responds as if normal tissues are infected or somehow abnormal. Inflammation involves immune cells, blood vessels, and molecular mediators. The purpose of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and to initiate tissue repair. signs of acute inflammation are pain, heat, redness, swelling, and loss of function

Therapies

Inflammation Therapy is a treatment for chronic disease involving a combination of lifestyle factors and medications designed to enable the immune system to fight the disease. Techniques used include heat therapy, cold therapy, electrical stimulation, traction, massage, and acupuncture. Heat increases blood flow and makes connective tissue more flexible. It temporarily decreases joint stiffness, pain, and muscle spasms. Heat also helps reduce inflammation and the buildup of fluid in tissues (edema). Heat therapy is used to treat inflammation (including various forms of arthritis), muscle spasm, and injuries such as sprains and strains. Cold therapy Applying cold may help numb tissues and relieve muscle spasms, pain due to injuries, and low back pain or inflammation that has recently developed. Cold may be applied using an ice bag, a cold pack, or fluids (such as ethyl chloride) that cool by evaporation. The therapist limits the time and amount of cold exposure to avoid damaging tissues and reducing body temperature (causing hypothermia). Cold is not applied to tissues with a reduced blood supply (for example, when the arteries are narrowed by peripheral arterial disease).

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

7th International Conference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands ; 5th European Immunology Conferences, July 21-23, 2016 Berlin, Germany; 2nd International Conference on Antibodies and Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; International Conference on Tumor Immunology and Immunotherapy, July 28-30, 2016 Melbourne, Australia; International Conference on Cancer Immunology and Immunotherapy, July 28-30, 2016 Melbourne, Australia; InternationalcongressonImmunology, August 21-26, 2016, Australia; 18th International Conference on Inflammation, Amsterdam, Netherlands, May 12 - 13, 2016; 14th Cytokines & Inflammation Conference 2526 January 2016 San Diego, United States;

Track 4:Molecular and Structural Immunology

Molecular Immunology

Molecular immunology deals with immune responses at cellular and molecular level. Molecular immunology has been evolved for better understanding of the sub-cellular immune responses for prevention and treatment of immune related disorders and immune deficient diseases. Journal of molecular immunology focuses on the invitro and invivo immunological responses of the host. Molecular Immunology focuses on the areas such as immunological disorders, invitro and invivo immunological host responses, humoral responses, immunotherapies for treatment of cancer, treatment of autoimmune diseases such as Hashimotos disease, myasthenia gravis, rheumatoid arthritis and systemic lupus erythematosus. Treatment of Immune deficiencies such as hypersensitivities, chronic granulomatous disease, diagnostic immunology research aspects, allografts, etc..

Structural Immunology

Host immune system is an important and sophisticated system, maintaining the balance of host response to "foreign" antigens and ignorance to the normal-self. To fulfill this achievement the system manipulates a cell-cell interaction through appropriate interactions between cell-surface receptors and cell-surface ligands, or cell-secreted soluble effector molecules to their ligands/receptors/counter-receptors on the cell surface, triggering further downstream signaling for response effects. T cells and NK cells are important components of the immune system for defending the infections and malignancies and maintaining the proper response against over-reaction to the host. Receptors on the surface of T cells and NK cells include a number of important protein molecules, for example, T cell receptor (TCR), co-receptor CD8 or CD4, co-stimulator CD28, CTLA4, KIR, CD94/NKG2, LILR (ILT/LIR/CD85), Ly49, and so forth.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

2nd International Conference and Exhibition on Antibodies and Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; 7th International Conference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd international conference on innate immunity, July 21-22, 2016, Germany; International Conference on Autoimmunity, October 13-14, 2016 Manchester, UK; Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA;9th EuropeanMucosal ImmunologyMeetings, October 9 - 12 October, Scotland;Immunology events;International Congress of Immunology

Track 5:Transplantation Immunology

Transplantation is an act of transferring cells, tissues, or organ from one site to other. Graft is implanted cell, tissue or organ. Development of the field of organ and tissue transplantation has accelerated remarkably since the human major histocompatibility complex (mhc) was discovered in 1967. Matching of donor and recipient for mhc antigens has been shown to have a significant positive effect on graft acceptance. The roles of the different components of the immune system involved in the tolerance or rejection of grafts and in graft-versus-host disease have been clarified. These components include: antibodies, antigen presenting cells, helper and cytotoxic t cell subsets, immune cell surface molecules, signaling mechanisms and cytokines that they release. The development of pharmacologic and biological agents that interfere with the alloimmune response and graft rejection has had a crucial role in the success of organ transplantation. Combinations of these agents work synergistically, leading to lower doses of immunosuppressive drugs and reduced toxicity. Significant numbers of successful solid organ transplants include those of the kidneys, liver, heart and lung.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

2ndInternationalCongress onNeuroimmunology&Therapeutics, Dec 01-03, 2016, USA; 7th International Conference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands ; 2nd International Conference on Antibodies and Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA;USA Immunology Conferences;International Conference on Tumor Immunology and Immunotherapy, July 28-30, 2016 Melbourne, Australia; International Conference on Cancer Immunology and Immunotherapy, July 28-30, 2016 Melbourne, Australia; British society for Immunology Annual Immunology Congress, 6-9 Dec, 2016, Liverpool, UK; InternationalConference onMucosalImmunology, July 28-29, 2016, Australia; Immunology events

Track 6:Infectious Diseases, Emerging and Reemerging diseases: Confronting Future Outbreaks

Infectious diseasesare disorders caused by organisms such as bacteria, viruses,fungior parasites. Many organisms live in and on our bodies. They're normally harmless or even helpful, but under certain conditions, some organisms may causedisease.Someinfectious diseasescan be passed from person to person. Many infectious diseases, such asmeaslesand chickenpox, can be prevented by vaccines. Frequent and thorough hand-washing also helps protect you from infectious diseases.

There are four main kinds of germs:

Bacteria - one-celled germs that multiply quickly and may release chemicals which can make you sick

Viruses- capsules that contain genetic material, and use your own cells to multiply

Fungi - primitive plants, like mushrooms or mildew

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

InternationalConference on Pediatric Care and Pediatric Infectious Disease, August 24-25, 2016 Philadelphia, Pennsylvania, USA; 4th InternationalCongress on Bacteriology and Infectious Diseases, May 16-18, 2016 San Antonio, Texas, USA; 2ndWorld Congress on Infectious DiseasesAugust 24 - 26, 2016 Philadelphia, Pennsylvania, USA; WorldCongress on Infection Prevention and Control, November 28-29, 2016 Valencia, Spain; Internationalconference on Emerging Infectious Diseases, Aug 24-26, Atlanta, Georgia;Immunology 2016, The 25th Annual CanadianConference on HIV/AIDSResearch Winnipeg, Manitoba, Canada , May 12, 2016 - May 15, 2016;Infectious DiseasesScandinavia-Russia Cruise 1626 June 2016, Copenhagen, Denmark; Immunology 2016, American Association of Immunologists, Annual Meeting May 13-17, Los Angeles, USA, 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands

Track 7:Autoimmune Diseases

An autoimmune disease develops when your immune system, which defends your body against disease, decides your healthy cells are foreign. As a result, your immune system attacks healthy cells. An autoimmune disorder may result in the destruction of body tissue, abnormal growth of an organ, Changes in organ function. Depending on the type, an autoimmune disease can affect one or many different types of body tissue. Areas often affected by autoimmune disorders include Blood vessels, Connective tissues, Endocrineglands such as the thyroid or pancreas, Joints Muscles, Red blood cells, Skin It can also cause abnormal organ growth and changes in organ function. There are as many as 80 types of autoimmune diseases. Many of them have similar symptoms, which makes them very difficult to diagnose. Its also possible to have more than one at the same time. Common autoimmune disorders include Addison's disease, Dermatomyositis, Graves' disease, Hashimoto's thyroiditis, Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Reactive arthritis. Autoimmune diseases usually fluctuate between periods of remission (little or no symptoms) and flare-ups (worsening symptoms). Currently, treatment for autoimmune diseases focuses on relieving symptoms because there is no curative therapy.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

International Conference on Autoimmunity, October 13-14, 2016 Manchester, UK; 2nd international conference on innate immunity, July 21-22, 2016, Germany; 2nd International Conference andExhibition on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA;Immunology events; 5th European Immunology Conferences, July 21-23, 2016 Berlin, Germany; 7th International Conference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; 2nd Conference on Rheumatic and Autoimmune Diseases, June 1 to 3, 2016 Nanjing, China; 18th International Autoimmune Diseases Meetings, Paris, France, September 26 - 27, 2016; British society for Immunology Annual Immunology Congress, 6-9 Dec, 2016, Liverpool, UK;International Congress of Immunology

Track 8:Viral Immunology: Emerging and Re-emerging Diseases

Immunology is the study of all aspects of the immune system in all organisms. It deals with the physiological functioning of the immune system in states of both health and disease; malfunctions of the immune system in immunological disorders (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection); the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo.

Viruses are strongly immunogenic and induces 2 types of immune responses; humoral and cellular. The repertoire of specificities of T and B cells are formed by rearrangements and somatic mutations. T and B cells do not generally recognize the same epitopes present on the same virus. B cells see the free unaltered proteins in their native 3-D conformation whereas T cells usually see the Ag in a denatured form in conjunction with MHC molecules. The characteristics of the immune reaction to the same virus may differ in different individuals depending on their genetic constitutions.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

6thInternational Conference andExhibition onImmunology,Oct 24-26, 2016, USA;InternationalConference onAutoimmunity, Oct 24-26, 2016, UK;5thEuropeanImmunologyConference, July 21-23, 2016, Germany; InternationalConference onCancer ImmunologyandImmunotherapy, July 28-30, 2016, Australia;International Conference onMucosal Immunology, July 28-29, 2016, Australia; 2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; InternationalConference on Tumor Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia; InternationalConference on Cancer Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia

Track 9:Pediatric Immunology

A child suffering from allergies or other problems with his immune system is referred as pediatric immunology. Childs immune system fights against infections. If the child has allergies, their immune system wrongly reacts to things that are usually harmless. Pet dander, pollen, dust, mold spores, insect stings, food, and medications are examples of such things. This reaction may cause their body to respond with health problems such as asthma, hay fever, hives, eczema (a rash), or a very severe and unusual reaction calledanaphylaxis. Sometimes, if your childs immune system is not working right, he may suffer from frequent, severe, and/or uncommon infections. Examples of such infections are sinusitis (inflammation of one or more of the sinuses), pneumonia (infection of the lung), thrush (a fungus infection in the mouth), and abscesses (collections of pus surrounded by inflamed tissue) that keep coming back.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

International Conference on Pediatric Care and Pediatric Infectious Disease, August 24-25, 2016 Philadelphia, Pennsylvania, USA; 7th International Conference on Pediatric Nursing and Healthcare, July 11-12, 2016 Cologne, Germany; International Congress on Pediatrics, 02-05 Jun 2016, Copenhagen, Denmark; 7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14;-15, 2016 Amsterdam, Netherlands; 2nd international conference on innate immunity, July 21-22, 2016, Germany; World Summit on Pediatric , 23 - 26 Jun 2016, Porto, Portugal; International Conference on Pediatric Nursing and Healthcare, Jul 11 - 13 2016, Cologne, Germany; Immunology 2016, American Association of Immunologists, Annual Meeting May 13-17, Los Angeles, USA; Immunology events;USA Immunology Conferences

Track 10:Immunotherapy & Cancer Immunotherapy: From Basic Biology to Translational Research

Immunotherapy is treatment that uses certain parts of a persons immune system to fight diseases such as cancer. This can be done in a couple of ways:

Stimulating your own immune system to work harder or smarter to attack cancer cells Giving you immune system components, such as man-made immune system proteins

Some types of immunotherapy are also sometimes called biologic therapy or biotherapy. In the last few decades immunotherapy has become an important part of treating some types of cancer. Newer types of immune treatments are now being studied, and theyll impact how we treat cancer in the future. Immunotherapy includes treatments that work in different ways. Some boost the bodys immune system in a very general way. Others help train the immune system to attack cancer cells specifically.

Cancer immunotherapy is the use of the immune system to treat cancer. The main types of immunotherapy now being used to treat cancer include:

Monoclonal antibodies: these are man-made versions of immune system proteins. Antibodies can be very useful in treating cancer because they can be designed to attack a very specific part of a cancer cell.

Immune checkpoint inhibitors: these drugs basically take the brakes off the immune system, which helps it recognize and attack cancer cells.

Cancer vaccines: vaccines are substances put into the body to start an immune response against certain diseases. We usually think of them as being given to healthy people to help prevent infections. But some vaccines can help prevent or treat cancer.

Other, non-specific immunotherapies: these treatments boost the immune system in a general way, but this can still help the immune system attack cancer cells.

Immunotherapy drugs are now used to treat many different types of cancer. For more information about immunotherapy as a treatment for a specific cancer, please see our information on that type of cancer.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

2nd International Conference and Exhibition on Antibodies and Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; InternationalConference on Tumor Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia; InternationalConference on Cancer Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia, 2nd internationalCongress on Neuroimmunology& therapeutics, Dec 01-03, 2016, USA;International Congress of Immunology;2nd international conference on innate immunity, July 21-22, 2016, Germany;5th European Immunology Conferences, July 21-23, 2016 Berlin, Germany; 9th European Mucosal Immunology meetings, October 9 - 12 October, Scotland; international congress on immunology, august 21-26, 2016, Australia; 4th European Immunology events September 6-9, 2015, Austria

Track 11:Immunology and Diabetes

Immunologyis the study of the immune system, which is responsible for protecting the body from foreign cells such as viruses, bacteria and parasites. Immune system cells called T and B lymphocytes identify and destroy these invaders. Thelymphocytesusually recognize and ignore the bodys own tissue (a condition called immunological self-tolerance), but certain autoimmune disorders trigger a malfunction in the immune response causing an attack on the bodys own cells due to a loss ofimmune tolerance.

Type 1 diabetes is anautoimmune diseasethat occurs when the immune system mistakenly attacks insulin-producing islet cells in the pancreas. This attack begins years before type 1 diabetes becomes evident, so by the time someone is diagnosed, extensive damage has already been done and the ability to produceinsulinis lost.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

InternationalConference onMucosalImmunology, July 28-29, 2016, Australia; International Conference onAllergy, March 29-30, 2016, Spain; 2ndInternationalCongress onNeuroimmunology&Therapeutics, Dec 01-03, 2016, USA;7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; Asthma EventsSeptember 14-15, 2016 Amsterdam, Netherlands;2nd InternationalConference on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; InternationalConference on Tumor Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia; InternationalConference on Cancer Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia; Immunology events InternationalcongressonImmunology, August 21-26, 2016, Australia; British society for Immunology Annual Immunology Congress, 6-9 Dec, 2016, Liverpool, UK

Track 12:Immune Tolerance

Immunological toleranceis the failure to mount animmuneresponse to an antigen. It can be: Natural or "self"tolerance. This is the failure (a good thing) to attack the body's own proteins and other antigens. If the immunesystem should respond to "self",an autoimmune diseasemay result. Natural or "self" tolerance: Induced tolerance: This is tolerance to externalantigens that has been created by deliberately manipulating theimmune system.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

InternationalConference onMucosalImmunology, July 28-29, 2016, Australia; International Conference onAllergy, March 29-30, 2016, Spain; 2ndInternationalCongress onNeuroimmunology&Therapeutics, Dec 01-03, 2016, USA;7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; Asthma EventsSeptember 14-15, 2016 Amsterdam, Netherlands;2nd InternationalExhibition on Antibodiesand Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA; InternationalConference on Tumor Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia; InternationalConference on Cancer Immunologyand Immunotherapy, July 28-30, 2016 Melbourne, Australia; Immunology events InternationalcongressonImmunology, August 21-26, 2016, Australia; British society for Immunology Annual Immunology Congress, 6-9 Dec, 2016, Liverpool, UK

Track 13:Vaccines and Immunotherapy

Vaccine is a biological preparation that improves immunity to particular disease. It contains certain agent that not only resembles a disease causing microorganism but it also stimulates bodys immune system to recognise the foreign agents. Vaccines are dead or inactivated organisms or purified products derived from them. whole organism vaccines purified macromolecules as vaccines,recombinant vaccines, DNA vaccines. The immune system recognizes vaccine agents as foreign, destroys them, and "remembers" them. The administration of vaccines is called vaccination. In order to provide best protection, children are recommended to receive vaccinations as soon as their immune systems are sufficiently developed to respond to particular vaccines with additional "booster" shots often required to achieve "full immunity".

Immunotherapy is treatment that uses certain parts of a persons immune system to fight diseases such as cancer. This can be done in a couple of ways:

Stimulating your own immune system to work harder or smarter to attack cancer cells

Giving you immune system components, such as man-made immune system proteins

Some types of immunotherapy are also sometimes called biologic therapy or biotherapy. In the last few decades immunotherapy has become an important part of treating some types of cancer. Newer types of immune treatments are now being studied, and theyll impact how we treat cancer in the future. Immunotherapy includes treatments that work in different ways. Some boost the bodys immune system in a very general way. Others help train the immune system to attack cancer cells specifically. Immunotherapy works better for some types of cancer than for others. Its used by itself for some of these cancers, but for others it seems to work better when used with other types of treatment.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

10th Euro Global Summit andExpo on Vaccines & VaccinationJune 16-18, 2016 Rome, Italy; 11th Global Summit andExpo on Vaccines, Vaccination and TherapeuticsSeptember 12-14, 2016 Phoenix, Arizona, USA; 12th Asia Pacific Global Summit andExpo on Vaccines & VaccinationNovember 24-26, 2016 Melbourne, Australia;International Congress of Immunology;7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands; International Conference on Autoimmunity, October 13-14, 2016 Manchester, UK;World Vaccine CongressApril 10-12, 2017 Washington; 10thVaccine Congress4-7 September 2016, Amsterdam, The Netherlands 10thVaccine Congress, 4-7 September 2016, Amsterdam British society for Immunology Annual Immunology Congress, 6-9 Dec, 2016, Liverpool, UK; 5th European Immunology Conferences, July 21-23, 2016 Berlin, Germany;USA Immunology Conferences

Track 14:Immunologic Techniques, Microbial Control and Therapeutics

Immunological techniques include both experimental methods to study the immune system and methods to generate or use immunological reagents as experimental tools. The most common immunological methods relate to the production and use of antibodies to detect specific proteins in biological samples. Various laboratory techniques exist that rely on the use of antibodies to visualize components of microorganisms or other cell types and to distinguish one cell or organism type from another. Immunologic techniques are used for: Quantitating and detectingantibodiesand/orantigens, Purifying immunoglobulins, lymphokines and other molecules of the immune system, Isolating antigens and other substances important in immunological processes, Labelling antigens and antibodies, Localizing antigens and/or antibodies in tissues and cells, Detecting, and fractionatingimmunocompetent cells, Assaying forcellular immunity, Documenting cell-cell interactions, Initiating immunity and unresponsiveness, Transplantingtissues, Studying items closely related to immunity such as complement,reticuloendothelial systemand others, Molecular techniques for studying immune cells and theirreceptors, Imaging of the immune system, Methods for production or their fragments ineukaryoticandprokaryotic cells.

Microbial control:

Control of microbial growth, as used here, means to inhibit or prevent growth of microorganisms. This control is achieved in two basic ways: (1) by killing microorganisms or (2) by inhibiting the growth of microorganisms. Control of growth usually involves the use of physical or chemical agents which either kill or prevent the growth of microorganisms. Agents which kill cells are called cidal agents; agents which inhibit the growth of cells (without killing them) are referred to as static agents. Thus, the term bactericidal refers to killing bacteria, and bacteriostatic refers to inhibiting the growth of bacterial cells. A bactericide kills bacteria, a fungicide kills fungi, and so on. In microbiology, sterilization refers to the complete destruction or elimination of all viable organisms in or on a substance being sterilized. There are no degrees of sterilization: an object or substance is either sterile or not. Sterilization procedures involve the use of heat, radiation or chemicals, or physical removal of cells.

Related: Immunology Conferences|Immunologists Meetings|Conference Series LLC

2nd international conference on innate immunity, July 21-22, 2016, Germany; 2nd International Conference and Exhibition on Antibodies and Therapeutics, July 11-12, 2016 Philadelphia, Pennsylvania, USA;7th InternationalConference on Allergy, Asthma and Clinical Immunology, September 14-15, 2016 Amsterdam, Netherlands, September 14-15, 2016 Amsterdam, Netherlands;International Conference on Autoimmunity, October 13-14, 2016 Manchester, UK; Immunology 2016, American Association of Immunologists, Annual MeetingMay 13-17, Los Angeles, USA;9th EuropeanMucosal Immunology meetings, October 9 - 12 October, Scotland;

Track 15:Immunodeficiency

Immunodeficiency is a state in which theimmune system's ability to fightinfectious diseaseis compromised or entirely absent. Immunodeficiency disorders prevent your body from adequately fighting infections and diseases. An immunodeficiency disorder also makes it easier for you to catch viruses and bacterial infections in the first place. Immunodeficiency disorders are often categorized as either congenital or acquired. A congenital, or primary, disorder is one you were born with. Acquired, or secondary, disorders are disorders you get later in life. Acquired disorders are more common thancongenital disorders. Immune system includes the following organs: spleen, tonsils, bone marrow, lymph nodes. These organs make and release lymphocytes. Lymphocytes are white blood cells classified as B cells and T cells. B and T cells fight invaders called antigens. B cells release antibodies specific to the disease your body detects. T cells kill off cells that are under attack by disease. An immunodeficiency disorder disrupts your bodys ability to defend itself against these antigens. Types of immunodeficiency disorder are Primary immunodeficiency disorders & Secondary immunodeficiency disorders.

Primary immunodeficiency disorders are immune disorders you are born with. Primary disorders include:

X-linked agammaglobulinemia (XLA)

Common variable immunodeficiency (CVID)

Severe combined immunodeficiency(SCID)

Secondary disorders happen when an outside source, such as a toxic chemical or infection, attacks your body. Severe burns and radiation also can cause secondary disorders.

Original post:
Worlds Leading Immunology Congress | Conferenceseries

Posted in Cell Therapy | Comments Off on Worlds Leading Immunology Congress | Conferenceseries

National Center For Regenerative Medicine

Posted: October 17, 2016 at 7:46 am

Exploradio: Cleveland's growing stem cell scene

The next breakthrough in medicine could come from a small group of entrepreneurs in Northeast Ohio. Stem cell research has a long-history in Cleveland, but the region is having a hard time building a biotech industry around it.

In this week's Exploradio, WKSU's Jeff St.Clair looks at the science and business of stem cell therapy. Read more

Case Western Reserve University Hosts Cancer Stem Cell Conference

All this week, researchers from across the world are gathering in Cleveland to attend Case Western Reserve University's cancer stem cell conference. For Ohio Public Radio, WCPN's Anne Glausser brings us an update on this field of science and how it is informing new cancer therapies.

"[Cancer stem cells] are the drivers," Gerson says. "They're the fundamental reason that we can't cure cancer today and why new treatments that are designed to first get rid of the bulk of the tumor and then immediately come back and go after the cancer stem cell are so important." Read more

NCRM Instrument Featured in Nature Biotechnology Article

A photograph of the "X-Evo Instrument" at the NCRM's OH-Alive Platform for robotic media preparation and automated cell culture. was featured the August 2014 issue of Nature Biotechnology article. The article discusses what governmental agencies can do to lower the risk of cell therapies and the enterprises commercializing them. Read More

Stem Cells Hold Keys to Body's Plan

Case Western Reserve researchers have discovered landmarks within pluripotent stem cells that guide how they develop to serve different purposes within the body. This breakthrough offers promise that scientists eventually will be able to direct stem cells in ways that prevent disease or repair damage from injury or illness. The study and its results appear in the June 5 edition of the journal Cell Stem Cell. Read more

NCRM Receives Ohio Third Frontier Grant for Therapeutic Cell Center

The Ohio Third Frontier Commission unanimously awarded Case Western Reserve University National Center for Regenerative Medicine (NCRM), $2.4 million for its OH-Alive Innovator Platform: A Process and Manufacturing Platform for Cell Therapy. These funds must be matched by NCRM and its collaborators so this represents a total investment of $4.8 million. The OH-Alive platform will help advance Ohio as one of the leading regions for stem cell therapy in the country by establishing a facility that will provide expertise in determining optimized conditions for producing stem cells for therapeutic purposes. Read more

Visit link:
National Center For Regenerative Medicine

Posted in Ohio Stem Cells | Comments Off on National Center For Regenerative Medicine

Update: Ohio Stem Cell Study Recruiting People with MS …

Posted: October 17, 2016 at 7:46 am

Summary: Investigators in Ohio are recruiting 24 people with relapsing forms of MS for a study of the safety and tolerability of transplanting ones own mesenchymal stem cells (derived from bone marrow). The study is being conducted at Cleveland Clinic Mellen MS Center, University Hospitals Case Medical Center, and the National Center for Stem Cell and Regenerative Medicine, all in Cleveland. This first trial of these cells for MS in the U.S. is supported by the Congressionally Directed Medical Research Programs, a program funded through the Defense Department, thanks in large part to the tireless work of MS activists across the country who helped to secure the funding. Please note: This study involves numerous visits to the study site.

Rationale: There are many types of stem cells, and varying degrees of research and knowledge about different types of stem cells and their potential usefulness for treating MS. At present, there has been no proven therapy for MS that uses stem cells. Read moreabout stem cells in MS.

One type of procedure that has been explored for several years in MS is called autologous hematopoietic (blood cell-producing) stem cell transplantation. This procedure has been used in attempts to reboot the immune system. These stem cells (derived from the bone marrow or blood) are stored, and the rest of the individuals immune cells are destroyed by chemotherapy or radiation or both. Then the stored stem cells are reintroduced by injection. Eventually they grow and repopulate the body with immune cells. The hope of that as yet experimental procedure is that the new immune cells will no longer attack myelin or other brain tissue, so that the person has perhaps a completely new immune system.

Another line of stem cell research in MS relates to efforts to repair nervous system damage. This research is in its infancy, and there is no evidence yet that any types of stem cells can reverse MS damage or restore function. There are a few known research studies being conducted by researchers who are attempting in a controlled fashion to safely test the ability of mesenchymal stem cells to treat MS damage.

Mesenchymal stem cells, which are present in many tissues of the body, potentially have the ability both to treat immune disorders and promote tissue repair. This phase I clinical trial in Cleveland is testing the ability of an individuals own mesenchymal stem cells isolated from the bone marrow to both inhibit immune mechanisms and to augment intrinsic tissue repair processes in people with relapsing forms of MS. Unlike previous bone marrow transplant studies, in this study the persons immune cells are not destroyed before the stem cells are infused. This study is supported by the Congressionally Directed Medical Research Programs, a program funded through the Defense Department, thanks in large part to the tireless work of MS activists across the country who helped to secure the funding.

Eligibility and Details: Participants should be ages 18 to 55, and have a diagnosis of relapsing MS, with active disease during the previous 24 months. This study involves numerous criteria for including or excluding participants. Further details can be obtained from http://clinicaltrials.gov (search for study# NCT00813969) or the contacts below.

The treatment involves a single intravenous infusion of mesenchymal stem cells that have been previously removed from the participants bone marrow and expanded in the laboratory. The study involves several safety assessments, blood tests, neurologic assessments, MRI scans and others tests over six months.

The primary goal of the study is to determine the feasibility, safety and tolerability of the procedure. Secondary goals include assessing the effects on MS disease activity and severity, as measured by clinical, MRI, and other testing.

Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please contact:

Sarah Planchon Pope, PhD Program Manager planchs@ccf.org 216-636-1232

OR

Cynthia Schwanger, RN, MSCN, CCRP Research Nurse schwanc@ccf.org 216-445-5788

Download a brochure that discusses issues to think about when considering enrolling in an MS clinical trial (PDF).

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Visit link:
Update: Ohio Stem Cell Study Recruiting People with MS ...

Posted in Ohio Stem Cells | Comments Off on Update: Ohio Stem Cell Study Recruiting People with MS …

Stem Cell Transplant Program – Cleveland, Ohio

Posted: October 17, 2016 at 7:46 am

UH Cleveland Medical Centers Stem Cell Transplant Program has received international recognition by the Foundation for the Accreditation of Cellular Therapy (FACT). Learn more.

University Hospitals Stem Cell Transplant Program offers excellence in cancer treatment for pediatric and adult patients. Located at UH Seidman Cancer Center in Cleveland, Ohio, the Stem Cell Transplant Program provides the latest innovations with superior outcomes for patients with leukemia, lymphoma and other hematologic (blood) types of cancer.

Experts in the Stem Cell Transplant Program provide specialized treatments, aiming to find the best therapy for each patient.

Our comprehensive program offers cord blood, blood, and marrow transplants for a range of hematologic cancers and other disorders using either the patients own stem cells or those donated by a family member or unrelated volunteer.

At UH Seidman Cancer Center, we take pride in offering a comprehensive approach to cancer treatment. Patients who seek care have access to a multidisciplinary team that includes:

After meeting with the patient, our experts develop a highly unique treatment plan based on each individuals specific needs and preferences. Transplant patients are evaluated and cared for by a team whose objective is to increase coordination of care and improve outcomes. Our team also works closely with the Blood and Bone Marrow Transplant Centerat University Hospitals Rainbow Babies & Childrens Hospital to treat children with hematologic cancers and other blood disorders.

As an affiliate of the National Marrow Donor Program, our bone marrow transplant program is among the most accomplished and respected nationwide. Some of the UH Stem Cell Transplant Programs accomplishments include the following:

Other accomplishments in the field of stem cell therapy include:

In addition, we are aggressively pursuing innovative treatment developments through stem cell therapy clinical trials combining chemotherapy, radiation therapy, biological therapy and stem cell transplantation.

Read this article:
Stem Cell Transplant Program - Cleveland, Ohio

Posted in Ohio Stem Cells | Comments Off on Stem Cell Transplant Program – Cleveland, Ohio

Stem Cell Therapy – North Kansas City Hospital, Kansas …

Posted: October 14, 2016 at 3:50 pm

Patients with severe critical limb ischemia (CLI) have an exciting new treatment option autologous stem cell therapy. Karl Stark, MD, FACS, with Kansas City Vascular, PC, is currently running two clinical trials with "incredible results," he says.

"This new stem cell therapy is a game changer for patients at high risk for losing a limb and for whom nothing else works," says Dr. Stark. "We have been looking for a viable treatment for a long time, and these new trials show the greatest promise." He has been involved in four clinical trials. The first two involved IV infusion of prostaglandins and the second was hyperbaric oxygen therapy but the results were not as profound as what his patients are experiencing with the two current stem cell trials.

CLI is the most severe form of peripheral artery disease. Its differentiated from acute limb ischemia in the duration of the process and the underlying etiology. Acute limb ischemia is usually embolic or thrombotic occlusion of the arteries of the leg.

Of patients with CLI, 25% will die within one year; 40% within 5 years. The one-year amputation rate is 25%, with the mortality risk 5-10% for BKA and 10-15% for AKA. In addition, quality of life and the ability to live independently decrease with an amputation.

Surgical revascularization involves using bovine carotid artery conduit when autologous vein is not available for bypass. It restores blood flow to the affected limb, and gives patients a better chance of survival than amputation. The same holds true for CLI patients, Dr. Stark reports.

Nondirect revascularization treatment options for patients with no reconstructable arteries include hyperbaric oxygen therapy. Clinical trial results included higher limb salvage rates and lower mortality rates. Patients were also twice as likely to heal their ischemic wounds.

Survival of patient with CLI and non-reconstructable arterial disease

For a specific group of patients, cell therapy appeared to be an option when other modalities proved inadequate or not possible:

The goal of cell therapy is angiogenesis. In Dr. Starks clinical trials, adult or autologous stem cells are used, which are harvested from bone marrow. Differentiated centrifugation separates cells into subgroups and then further separates them into tissue specific-types . An intra-arterial and/or intramuscular injection protocol then deposits cells in the neurovascular bundle.

Lifecells has developed the protocol Dr. Stark is using for harvesting and selecting the most effective stem cells. And because the work is with autologous stem cells, the process is safer, avoids moral issues and has fewer complications.

It takes 4 to 6 weeks to see results. Since limbs must be healthy enough to withstand this time period, seeing patients early in their disease is important. Early results show improved limb salvage rates at 60%. There is also improved limb perfusion as measured by ankle brachial index and TC02. Interim data also show improvement in ischemic rest pain and ulcer healing.

"We are seeing a lot of interest from around the country in our stem cell clinical trials," Dr. Stark noted. "North Kansas City Hospital is at the forefront of this research, and its an honor to work with referrals from some of the leading vascular surgery centers."

Dr. Starks presentation

Dr. Stark earned his medical degree from the University of Missouri-Kansas City. He completed his residency in general surgery at Truman Medical Center and a fellowship in vascular surgery at Middlesex General University Hospital, New Jersey. Dr. Stark is the Midwest medical director for Healogics and director of the Wound Healing Center at North Kansas City Hospital.

To learn more call, 816.872.1598.

See the rest here:
Stem Cell Therapy - North Kansas City Hospital, Kansas ...

Posted in Kansas Stem Cells | Comments Off on Stem Cell Therapy – North Kansas City Hospital, Kansas …

Stem Cell Therapy Tulsa OK | Cushing OK | Sapulpa OK

Posted: October 9, 2016 at 9:46 pm

Stem Cell Therapy in Tulsa, Oklahoma Stem Cell Injections for Arthritis, Tendonitis, Knee Pain & More

As an alternative to surgery, our patients can now benefit from injections of platelet - rich plasma, amniotic, bone marrow or adipose stem cells to treat chronic orthopaedic conditions. These treatments can reduce pain and provide long lasting relief from chronic tendinitis, early arthritis and cartilage damage in the joint.

Our surgeons offer these fairly new treatment options; PRP, amniotic membrane stem cell, bone marrow stem cell as well as adipose stem cell injections to successfully treat patients with knee, hip or shoulder osteoarthritis, rotator cuff tendonitis, Achilles tendonitis, chronic bursitis, meniscal tears and degenerative arthritis. (For clarification, amniotic stem cells comes from the amniotic sac not an embryo. While some people may have ethical issues with embryonic stem cell therapy, most people agree the use of amniotic stem cell therapy raises no ethical or moral questions.)

As we age, our bodies undergo wear and tear from previous injuries, exercising, playing sports or arthritis. We do not repair these injures as well as we did when we were young. We produce less of our repair cells (mesenchymal stem cells) as we get older so it takes longer to recover.

Stem cell treatment takes advantage of the bodys ability to repair itself. With amniotic stem cell therapy, Dr. Mittal injects stem cells from amniotic tissues into your body. These stem cells have anti-inflammatory properties, similar to steroid and cortisone shots. Whats great is stem cell therapy can go beyond the benefits of standard injection therapy. Stem cells can actually restore degenerated tissue while providing pain relief. The growth factors in amniotic stem cells may replace damaged cells in your body. Stem cell injections also contain hyaluronic acid which lubricates tendons and joints which eases pain and helps to restore mobility.

One of the richest sources of stem cells is bone marrow, and the hip (pelvis) is one of the best and most convenient locations for obtaining bone marrow. During the harvesting procedure, the doctor removes (or aspirates) your cells from the pelvis. A trained nurse or technician then uses specifically designed equipment to concentrate the stem cells in the bone marrow and provides the cells back to the surgeon for implantation at the site of injury. This technique can be performed in one of our procedure rooms at the clinic.

A small sample of Adipose tissue (fat) is removed from above the Superior Iliac spine (love handles) or abdomen under a local anesthetic. Then a trained nurse or technician uses specifically designed equipment to concentrate the adipose stem cells and provides the cells back to the surgeon for implantation at the site of injury. This technique can be performed in one of our procedure rooms at the clinic.

Amniotic Stem Cell injections provide patients with a non-surgical treatment option to reduce various types of musculoskeletal pain. The injections are performed under Ultrasound guidance to ensure proper placement of the stem cells. With amniotic stem cells, there is no threat of patient rejection and amniotic fluid is highly concentrated source of stem cells, which makes this type of stem cell injection preferable.

Yes, more than 10,000 injections have been performed without a single reported adverse side effect. The use of amniotic stem cells is well researched, safe and effective, plus they have been used by ophthalmologists and plastic surgeons for around 20 years.

No, PRP is the injection or addition of blood platelets to enhance or jump-start the healing of soft tissue. Stem cell therapy is the process of using stem cells to create new cells to promote damaged or lost cells. They are different treatments but fall in the category of regenerative medicine.

To develop a PRP preparation, blood must first be drawn from a patient. The platelets are separated from other blood cells and their concentration is increased during a process called centrifugation. The increased concentration of platelets is then injected back into the region of the body being treated. This technique can also be performed in one of our clinic procedure rooms.

While PRP and stem cell therapy has been used for years to treat a multitude of injuries, their application is fairly new to orthopaedics. Due to this, some insurance companies may deny coverage making these procedures self-pay. In most cases its close to the amount of your deductible if you did in fact have a surgery. Our business office will be happy to work with you to obtain alternative payment arrangements prior to scheduling any procedure.

If you are suffering from any kind of joint, tendon or ligament pain and most other conservative treatments arent alleviating it then you may be a candidate for amniotic stem cell therapy. However if you have severe degenerative osteoarthritis you may not be eligible. If you believe you are a candidate then please fill out the form to the right to schedule a consultation appointment with one of our surgeons. They will look at your X-rays and examine you to determine if you are a candidate for one of these regenerative treatments.

Post-Procedure Instructions for Joints

Immediately After Your Cell Transplant Procedure: The stem cell injection includes producing a micro injury in the joint. As a result, expect the joint to be sore. This can be everything from minimally sore to very sore. Activity: The goal is to allow the stem cells to attach and then to protect them while they differentiate into cartilage. For this reason, youll be asked to keep the joint as still as possible for 30-60 minutes after the procedure. Do not take a bath for three days, but a shower 12 hours after the procedure is fine. 1st 3rd Day: For the first day, you should limit activity on the joint. If you have post-op soreness this may be easy to do, as you may have a natural limp or antalgic gait (your body does this to reduce pressure on the area to allow healing). If you dont have this, then simply, naturally taking a bit of weight off this area as you walk is a good idea this first day. Avoid all contact sports as well as jogging, running, or sports that involve impact on that joint. 4th Day 2nd Week: You can start to walk normally, no more than 30-60 minutes a day. Avoid all contact sports as well as jogging, running, or sports that involve impact on that joint. Bike riding is fine as are stationary bikes (no up/downs), elliptical machines, and swimming (no breast stroke). 3rd 6th Week: Avoid all contact sports as well as jogging, running, or sports that involve impact on that joint. You can walk as much as you like. Bike riding is fine, as are stationary bikes, elliptical machine, and swimming. Stem Cell Therapy Testimonials

View post:
Stem Cell Therapy Tulsa OK | Cushing OK | Sapulpa OK

Posted in Oklahoma Stem Cells | Comments Off on Stem Cell Therapy Tulsa OK | Cushing OK | Sapulpa OK

Regenerative Medicine | Nevada Pain – Las Vegas, Henderson

Posted: October 9, 2016 at 9:45 pm

What is Regenerative Medicine? Regenerative Medicine Explained by Las Vegas, Summerlin, and Henderson Nevadas Top Pain Doctors

Regenerative medicine is a rapidly evolving, advanced technology in the management of many acute and chronic pain conditions. Chronic pain is a common condition that can cause numerous detrimental impacts on an individuals ability to function on a day-to-day basis. Musculoskeletal pain, specifically, has historically been regarded as the number one cause of chronic disability in the United States. Further, chronic musculoskeletal pain has also been found to be the leading contributing factor to higher rates of physician appointments. Across both acute and chronic conditions, prevalence rates have estimated that approximately 100 million adults experience difficulties with regard to back pain every year. Regenerative medicine has not been approved to treat all cases of pain; however, depending on the individuals specific pain condition, regenerative medicine may be considered as an appropriate and effective treatment.

Drawing from research in the areas of biology, chemistry, computer science, engineering, genetics, medicine, and robotics, regenerative medicine involves the construction of biological substitutes for many of the tissues found in the body. The general idea behind regenerative medicine, or tissue engineering, is drawing from the work of science and technology so that researchers are able develop biological substitutes, which will act to restore, maintain, and improve the functioning of damaged or lost tissue.

Regenerative medicine is a relatively new procedure, though its origins date back as early as 1962, when the first synthetic skin substitute was used. While there are many misconceptions maintained regarding regenerative medicine, advances in technology have allowed for the development of new procedures for treating many common orthopedic conditions, which do not require an operation. In fact, many of the regenerative medicine interventions are minimally invasive. The common orthopedic conditions that have been successfully treated through the use of regenerative medicine procedures include arthritis, as well as injuries to the bodys cartilage, spinal discs, bone, tendons, ligaments, muscle, or other bodily tissue.

Regenerative medicine is believed to have originally emerged from a number of scientific and technological advances that span a diverse spectrum of fields. Also known as tissue engineering, regenerative medicine utilizes existing living tissue cells and biocompatible materials, along with both biochemical (such as growth factors found in the body) and physical factors to generate tissue-like constructs that may be used to repair tissue that has been damaged as the result of an injury or to replace an organ failing as the result of normal aging.

Tissue-based procedures related to regenerative medicine originated from early techniques in skin grafting. Originally developed in 1962, the first successful tissue-engineered procedures were performed in the 1970s. Beginning by harvesting a skin biopsy, Howard Green and his colleagues at Harvard Medical School perfected techniques in growing skin epidermis. This technology has also historically been applied clinically to help individuals with other conditions. Since the 1960s, regenerative therapy has drawn from stem cell technology to provide bone marrow transplants to help individuals suffering from leukemia.

For a number of years, scientists have been interested in stem cells because of their regenerative properties, as well as their ability to develop into any type of tissue that is found within the body. It is for these reasons that stem cells contain the potential for what is believed to be limitless clinical applications in the health care field. In fact, stem cell research is advancing the treatment options available as well as improving treatment outcome rates for diseases, such as Parkinsons disease, Type I diabetes, heart disease, Duchenes muscular dystrophy, Alzheimers disease, stroke, osteoarthritis, rheumatoid arthritis, and vision and hearing loss. This technology has also been utilized in the treatment of injuries, such as spinal cord injuries and severe burns. There are many scientists and researchers who firmly maintain the hope that in the future stem cell technology will lead to the possibility of repairing and replacing damaged or diseased tissue.

Indeed, the first tissue to be bioengineered was the skin. Following this, scientists were also able to successfully bioengineer cartilage. Both of these products, which were produced through tissue engineering, are available commercially to health care providers today. While these products arose on the market quickly and inspired enthusiasm for the possibility of generating all of the types of tissue that make up the human body through the use of tissue engineering, there are a number of problems that have prevented this progress. For example, both skin tissue and cartilage tissue do not require extensive vascularization, as other types of tissue do. This means that the generating process to engineer the tissue of both skin and cartilage can be completed using more simplified techniques, such as merely combining cells together.

Driven particularly by the discoveries of the bodys own ability to organize itself and regenerate tissue following cell death or loss, the primary goal of regenerative medicine, or tissue engineering, for pain, is to generate new tissue to replace tissue that has been injured, diseased, or is degenerating owing to advancing age.

Given that regenerative medicine involves the use of living cells, however, there are a number of ethical and legal issues surrounding the use of platelet-rich plasma and particularly that of embryonic stem cells. Of utmost importance in regenerative medicine is mimicking the environment from which the stem cells were drawn. While the FDA does not currently maintain any approval requirements with regard to adult stem cells, stem cell therapy does not currently have FDA approval. Moreover, physicians frequently go off label, when prescribing patients a form of treatment. This essentially means that the physician believes another type of drug, which has not undergone any clinical trials for that specific diagnosis, would greatly benefit the patient.

Of utmost importance in regenerative medicine is mimicking the environment from which the stem cells were drawn. This will allow the engineered cells to function as if they are still in their native tissue. In terms of musculoskeletal chronic pain, there are generally three types of regenerative medicine. These include the following.

One type of regenerative medicine is stem cell therapy. This procedure is believed to be ideal for patients experiencing low back or neck pain owing to a degeneration of the vertebral discs or joint pain owing to osteoarthritis, such as that in the knees, hips, or shoulders. Through cell division, stem cells are naturally able to renew themselves and to differentiate, or specialize, into a wide range of different types of tissue found within the body. As such, stem cells can also be found at many sites within the body, including human embryos, skin cells, bone marrow, peripheral blood, placental blood, placental tissue, and adipose tissue. There are two general types of stem cells found within the body, which include embryonic stem cells and adult stem cells.

Beginning in the 1960s, stem cell technology was used to effectively treat individuals needing bone marrow transplants, such as individuals suffering from leukemia. Currently, stem cell technology is regarded as an interventional procedure for the treatment of a number of chronic pain conditions. Generally, this procedure involves extracting the patients own stem cells and other supporting cells from one of the known sites for stem cells. This material is then purified, concentrated, and injected into the damaged tissue. It is important that this concentration is not altered in any way.

The procedure for stem cell therapy is generally non-surgical and there is very little recovery time. Thus, stem cell therapy can potentially help patients avoid surgery and the potential side effects that are associated with it. Most patients report some soreness at the site of the stem cell injection, which may or may not be accompanied by bruising. There have been no reports of serious side effects following stem cell therapy.

Another type of regenerative medicine for the treatment of chronic pain is amniotic membrane therapy. The human amniotic membrane is comprised of several unique properties that make it ideal for use in regenerative medicine. The amniotic membrane is composed of two types of cells: epithelial cells and stromal cells. Both the epithelial cells and the stromal cells exhibit characteristics that are similar to stem cells in that they are able to differentiate in vivo. Previous literature examining animal models on the use of amniotic membrane following a minimally invasive surgical procedure called a laminectomy has shown the amniotic membranes effectiveness in reducing epidural fibrosis and scar adhesion. Studies examining the use of the amniotic membrane in human models provide some evidence for its effectiveness. In particular, amniotic membrane use has been supported as an efficacious treatment for general tissue damage, such as tendonitis.

Similar to that of stem cells, the procedure for using amniotic membrane as an interventional therapy for the treatment of chronic pain conditions is generally non-surgical and there is very little recovery time. Thus, amniotic membrane procedures can provide the benefit of not undergoing surgery. This allows many patients to avoid going on disability or be subjected to the other side effects that can often occur following major surgery. Amniotic membrane therapy involves injecting a concentrated compound of the patients own amniotic membrane to the site of the injury. Most patients report some soreness at the site of the injection, which may or may not be accompanied by bruising.

The concentrated compound used in the platelet-rich plasma technique is created from a sample of blood from the patient. This blood is centrifuged to separate the almost-clear fluid called the serum (which is found as the top layer), the platelets and white blood cells (found in the middle), and the red blood cells (found at the bottom). Estimates have suggested that the middle layer is comprised of a platelet concentration of around one million platelets/uL. A typical platelet concentration would fall somewhere between 150,000-350,000 platelets/uL. Further, this fluid also contains highly concentrated (up to three to five times greater) growth factor. This concentrated compound is then injected into the site of the injury, where the platelets synthesize and release other active proteins. These actions are believed to account for the regenerative effect that platelet-rich plasma therapy has on damaged tissue. More specifically, the synthesizing of platelets and the release of proteins enhances the recruitment, proliferation, and differentiation of cells, which are the underlying processes in generating new tissue at the cellular level. Most patients report only some soreness at the site of the injection following the procedure, which may or may not be accompanied by bruising.

Platelet-rich plasma therapy has received an extensive amount of attention within the literature. In fact, platelet-rich plasma therapy has been shown to have beneficial effects on the expression of genes and matrix synthesis within tendons. Furthermore, platelet-rich plasma therapy is linked with the proliferation of cells and increases in total collagen production. Results from studies examining the effectiveness of platelet-rich plasma treatment have provided support for its benefits in treating lateral epicondylitis, patellar tendinopathy, Achilles tendinopathy, rotator cuff tendinopathy, rotator cuff tears, medial collateral ligament and anterior cruciate ligament tears, and osteoarthritis. Platelet-rich plasma therapy is also used to treat other acute and chronic pain conditions including tendonosis, muscle strain, muscle fibrosis, arthritis, arthrofibrosis, articular cartilage defects, meniscal injury, and chronic synovitis or joint inflammation. Given that platelet-rich plasma therapy for chronic pain is non-surgical, there is very little recovery time and very few risks.

Patients who are interested in whether or not regenerative medicine is an appropriate treatment option for providing relief for their pain condition are encouraged to seek out a consultation with a physician that is an expert in the area of regenerative medicine. This consultation will likely include an in-depth medical evaluation regarding the individuals underlying condition, and the potential for using regenerative medicine to treat the condition. This consultation will also include guidance from the expert physician regarding the procedures involved in regenerative medicine and what to expect. Indeed, many individuals hold misconceptions regarding the use and application of regenerative stem cell therapy; therefore, the consultation appointment serves to provide the patient with education regarding the process and to address any of the patients questions or concerns.

There are a number of pain conditions, including musculoskeletal conditions that are expected to benefit from regenerative medicine. During the initial consult with an expert physician in the area of regenerative medicine, your doctor will give you a medical evaluation consisting of a brief yet detailed personal history. The goal of this is to ensure an accurate diagnosis of the source of the pain, in order to determine the most appropriate regenerative medicine procedure. Indeed, in some cases of chronic pain, the precise cause is not identified. In these instances, the physician will want to ensure that certain diagnoses are ruled out. Your physician will also generally assess for your degree of risk for persistent difficulties.

Chronic pain can arise from a number of sources and many cases of chronic pain can originate because of a degenerative process or pathology. Damage to muscles, joints, or ligaments that comprise the spinal region can also be the main source of both acute and chronic pain. In general, back and neck pain is characterized by sensations of pain and discomfort that arises in the back and may radiate out toward the limbs. The specific symptoms or sensations of pain are widely varied. Some patients will experience the pain as a highly specific sharp stab, while others will describe the pain as more generalized and widespread. Further, the symptoms of chronic pain are expected to fluctuate over time. For instance, often dependent on environmental circumstances, a patient may fluctuate in and out of recurring symptoms and exacerbations of pain.

While the specific symptom clusters generally depend on the underlying cause, some common complaints include:

Pain experienced within the body is thought to provide a strong indication that there is likely tissue damage or an underlying injury. In general, a number of treatments available for these common conditions merely help the patient cope with the debilitating pain, rather than addressing the underlying injury. New technology in the field of regenerative medicine has provided advancements in the types of treatments available for chronic pain. Indeed, these forms of treatment target the underlying problem, by promoting the body to heal itself through the use of stem cells.

Patients who suffer from the following list of conditions are potential candidates for regenerative medicine procedures.

Spondylolisthesis refers to the degenerative process of the individual bones of the spine, called the vertebrae. Most commonly caused by degenerative disc disease, spondylolisthesis is a condition that occurs when the vertebra becomes dislocated and slips over another. It is often referred to under nonspecific low back pain, because a large portion of patients with this anatomical deformity do not present with any related symptoms, including pain. During spondylolysis, the nerves around the weakened and slipped vertebrae can become compressed. Annual prevalence rates of within the general population estimate that approximately 12% of the population have had difficulties with regard to this condition.

Spinal stenosis is a common condition characterized by a restriction of the spinal canal, which is caused by a narrowing of the spinal column. The characteristic feature of spinal stenosis is neurogenic claudication, which is an inflammation of the nerves fanning out from the spinal cord. People with spinal stenosis often experience pain while walking. It is generally recommended that patients attempt more conservative forms of treatment prior to beginning regenerative medicine intervention.

These are genetically linked problems that relate to the curvature of the spine (e.g., scoliosis or kyphosis), and generally involve the entire spine. These difficulties are relatively uncommon. Recent prevalence rates are not available; however, early estimates suggest that spinal deformities occur in about 0.8% to 1.9% of the general population.

Degenerative disc disease is a condition related to the changes that occur within the intervertebral discs as people age. This aging of the intervertebral disc can cause tears, which is believed to be the source of the pain associated with degenerative disc disease. The pain associated with this particular disease can occur throughout the spine, however in some instances, the pain was reported to be localized to the affected intervertebral disc. Previous treatments for degenerative disc disease have generally been limited to physical therapy, over-the-counter or prescription pain medications, steroid injections, and spinal fusion surgery. New advances in technology have lead to the use of stem cell therapy for the treatment of degenerative disc disease. This involves extracting the patients own stem cells. This is typically done from the patients hip, as it is the ideal location for obtaining bone marrow. This marrow is then concentrated and injected into the site of the injury.

Herniated disc is a condition characterized by damaged intervertebral discs, causing them to bulge or break. The intervertebral discs within the spine column undergo a significant amount of daily stress. Over time, this stress is believed to cause the disc to rupture, bulge, or herniate. In other words, the material comprising the intervertebral disc expands, putting pressure on the spinal column as well as the surrounding nerves. This pressure from the bulging disc is believed to be the source of significant pain. Further, this condition is more commonly found among aging individuals. While physical therapy has shown some promise in terms of improving the condition of the herniated disc, it requires a significant portion of time. Other treatments include surgical procedures, which cut out and remove bulging or herniated disc material. This type of procedure involves a number of risks as the disc is significantly weaker following the surgery and removal of tissue, which is believed to place the individual at an increased risk for future difficulties. New techniques within the field of regenerative medicine include utilizing the patients stem cells and support cells (which includes platelets) to regenerate and rebuild the network of cells comprising the injured disc.

Plantar fasciitis is a common form of chronic pain within the heel and foot. The flat, thick connective tissue found on the bottom of the foot, which connects the ball of the foot to the heel is known at the plantar fascia. The plantar fascia creates support for the arch of the foot. When this connective tissue becomes strained, there is a risk for damage to occur in the form of tiny tears on the ligament itself. In general, treatments available for providing relief for the pain associated with plantar fascia only target the symptoms of pain. Thus, regenerative procedures are believed to be the ideal choice to treat the pain of plantar fascia, as they promote the bodys own process of healing damaged tissue. Indeed, several research studies have provided empirical support for the use of platelet rich plasma therapy as an effective therapy for plantar fascia.

The sacroiliac joint is large and located at the base of the spine, connecting the spine with the hip. In many instances of sacroiliac joint pain, the individual is able to identify the injury that occurred prior to the onset of pain. However, acute events do not account for all cases of sacroiliac joint pain. Presently, there are limited treatment options available for sacroiliac joint pain. Indeed, evidence in terms of the effectiveness of steroid injections, radiofrequency neurotomy, and pulsed radiofrequency for the treatment of pain related to this joint is generally poor. However, there is some evidence, albeit limited, that regenerative procedures are effective in providing the patient relief from pain. Further, some evidence exists that suggests that the benefits of prolotherapy last much longer than that of steroid injections.

Lumbar radiculopathy, which can also be known as sciatica, is believed to occur when a herniated disc (typically between the fifth lumbar (L5) and the first sacral spinal nerve (S1)) pushes against a nerve. This pain travels down the leg. The primary goal of therapy is to reduce the size of the bulging disc, thereby reducing the compressive effect the bulging disc had on the nerve root. While there are a number of treatments available for treating lumbar radiculopathy pain, should these treatments be ineffective in relieving patients from their pain, they may be an appropriate candidate for stem cell repair.

Cervical radioculopathy is a chronic pain condition that occurs when a disc in the neck is pushing against the cervical nerve causing pain to travel down the arms. This condition is commonly found among young adults either through a herniated disc or an injury. Older adults, however, struggling with these symptoms of neck pain, are expected to have osteophyte formation causing foraminal narrowing, decreased disc height, and degenerative changes in the intervertebral joints.

A small number of patients have back pain so severe and unremitting that they must have surgery in order to try and gain some relief. As a result of this surgery, some patients continue to suffer from ongoing symptoms of back pain. These cases are recognized as failed back surgery, as the goal of the original surgery was to provide the patient with relief from pain. In these cases, pain in the lower back is caused by scar tissue that develops around the spinal nerves of the epidural space following surgery. Other factors that likely explain pain that persists following back surgery include disc herniation, post-operative pressure that is persistently placed on the spinal nerve, and altered joint mobility. Individuals with a history of anxiety, depression, or difficulty falling asleep or staying asleep are considered to be at an increased risk for developing a chronic pain condition following back surgery. Symptoms of chronic pain that occurred as a result of failed back surgery primarily include diffuse, dull, and aching pain across the back and lower limbs. Additionally, some patients may experience sharp, pricking, or stabbing pain in the limbs. Provided that other treatments have failed at providing the individual with relief from pain, failed back surgery patients may be considered for treatment using regenerative medicine.

In general, the procedure takes approximately 30 minutes. The expert physician generally sees patients at a clinic and is able to complete the procedure without the use of general aesthesia. Further, by completing this procedure on an outpatient basis, there is no recovery period. In fact, individuals are able to return directly to work and their usual activities following the procedure.

Generally, regenerative medicine involves extracting the patients own stem cells and other supporting cells from one of the known sites for stem cells. This material is then purified, concentrated, and injected into the damaged tissue. It is important that this concentration is not altered in any way. Most individuals report very little discomfort from this procedure. Some minor soreness at the site of the injection may be reported. Further, patients may experience mild bruising.

Patients are expected to achieve a number of benefits through regenerative medicine, such as:

There are a number of treatments available to provide patients with relief from chronic pain. Following an accurate diagnosis by a physician specializing in pain conditions, it is generally recommended that patients who were referred for regenerative medicine first undergo an initial consultation with an expert pain specialist. While there is evidence that these treatments are beneficial to a wide variety of pain conditions, there are a number of individuals whose pain does not respond to treatment. For these individuals with intractable pain, more aggressive and long-term forms of treatment are available to combat their debilitating symptoms. Further, regenerative medicine is not approved for all pain conditions. Your doctor will help determine which treatment is right for you.

In terms of the procedure, regenerative medicine involves an extraction of the patients own stem cells and other supporting cells from one of the known sites for stem cells. This material is then purified, concentrated, and injected into the damaged tissue. It is important that this concentration is not altered in any way. Most individuals report very little discomfort from this procedure. Some minor soreness at the site of the injection may be reported. Further, patients may experience mild bruising, again, at the site of the injection. This procedure is generally regarded as safe and can be done on an outpatient basis.

Historically, very few studies exist regarding the effectiveness of regenerative medicine on many different pain conditions. However, evidence is mounting regarding its effectiveness for a range of pain conditions that failed to respond to first-line interventions. Improvements to the system and its procedure are impending, given the significant advances in technology. Thus, regenerative medicine may emerge in future studies as an ideal method of treating chronic pain.

NOTE: Adult stem cells are autologous, meaning that they are drawn from an adult patient and then returned to that same patient in the form of treatment. Presently, the FDA does not have any approval requirements in terms of the collection of adult stem cells. The FDA has not approved the use of stem cells to combat aging or to prevent, treat, or cure any disease or medical condition mentioned.

More:
Regenerative Medicine | Nevada Pain - Las Vegas, Henderson

Posted in Nevada Stem Cells | Comments Off on Regenerative Medicine | Nevada Pain – Las Vegas, Henderson

Stem Cell FAQs – Minnesota Regenerative Medicine

Posted: October 7, 2016 at 3:44 am

What is the benefit of stem cell treatment?

Stem cell injections provide a non-surgical treatment option to reduce pain and promote natural healing and regeneration, while still providing long-lasting relief from arthritic joint pain, chronic tendinitis, or damaged musculoskeletal tissue.

Who is a suitable candidate for stem cell treatment?

In general, stem cell injections are most appropriate for patients suffering from mild to moderate osteoarthritis affecting the knee, shoulder, hip, ankle, foot, hand, or digits. Stem cell injects are also appropriate for patients with chronic tendinitis, partially torn tendons, and damaged musculoskeletal tissues such as a rotator cuff, labrum, meniscus, ligament, and skeletal muscle.

Who is not a suitable candidate for stem cell treatment?

Conditions excluding a patient from being a suitable candidate for a stem cell treatment include: (1) a patient with lymphoma, leukemia, or active cancer not in remission for at least five years; (2) a patient with any current or active infection; (3) a patient needing to take blood thinners such as Coumadin; (4) a patient with a contraindication to having liposuction or autologous stem cell treatment or PRP therapy; (5) a patient with multiple or complex medical issues.

Which joints, tendons and musculoskeletal tissues can be treated with stem cells?

The most common joints treated with stem cells include the knee, shoulder, hip, ankle, hand, finger and toe. The most common tendons treated with stem cells involve those with chronic tendinitis or partial tears such as the shoulder rotator cuff, distal biceps tendon, medial or lateral elbow tendons, and Achilles tendon.

What are the risks of a stem cell treatment?

An orthopedic stem cell treatment to treat painful osteoarthritis or chronic tendinitis or degenerative musculoskeletal tissue uses your own stem cells. Since the cells come from your own fat, there is no chance of your body rejecting them as these cells promote or regenerate your bodys natural ability to heal. There is a small risk of infection during a stem cell treatment. You can expect some soreness at both the liposuction site and the stem cell injection site for a few days following the procedure.

What is the price of a stem cell treatment?

The final price of a stem cell treatment is determined by what type of stem cell injection is being done, the number of injections, and whether or not platelet-rich plasma (PRP) is used along with the stem cells.While the price can vary, the price for a stem cell injection with PRP into a single joint or tendonis $5900.The price for a stem cell injection with PRP into two or more areas may be more.

Orthopedic stem cell treatments with PRP using fluoroscopic or ultrasound guidance during injection are typically not a covered benefit of Medicare or private insurance.

Where is the stem cell therapy offered?

Our regenerative medicine specialists at Minnesota Regenerative Medicine provide stem cell treatments at our Hogue Clinics corporate headquarters only in Maple Grove, Minnesota. The entire stem cell treatment process takes five hours or less to perform.

What should I do if I think Im a suitable candidate?

If you live in the Minneapolis/St. Paul (Twin Cities) or surrounding areas, we recommend that you schedule an appointment for a consultation to determine if you are a suitable candidate for a stem cell with PRP treatment. To expedite this process, we recommend that you bring in your most recentradiology reportsfor any imaging studies performed, as well as any other pertinent medical records.

Where do the stem cells come from?

The stem cells used for a patients stem cell injection come from the patients own adipose tissue (fat).

What is the success rate of a stem cell treatment?

Since we began performing stem cell treatments in 2011, our experience is that most patients will experience some degree of pain relief and improvement starting within a few weeks to months following a stem cell with PRP treatment.

Sometimes, we recommend platelet-rich plasma (PRP) injections be performed monthly following the initial stem cell treatment to continue to nourish and stimulate the injected stem cells. Additional PRP treatments will incur a separate charge with each PRP treatment. Clinical improvement and pain relief continues for six months or longer, often up to a year or more, following a stem cell treatment. Of the dozens of patients we have treated so far with stem cell treatments, the majority of patients have self reported some degree of pain relief and improvement in musculoskeletal function. Very few patients have reported little to no improvement.

Does a stem cell treatment consist of one or multiple injections?

Typically we do from one to several stem cell injections per joint or tendon or targeted area. This may vary depending on the severity and complexity of the osteoarthritis or chronic tendinitis or degenerative musculoskeletal condition being treated.

Visit link:
Stem Cell FAQs - Minnesota Regenerative Medicine

Posted in Minnesota Stem Cells | Comments Off on Stem Cell FAQs – Minnesota Regenerative Medicine

Minnesota invests in regenerative medicine – Health Talk

Posted: October 7, 2016 at 3:44 am

Last year, the 2014 Minnesota legislative session brought a big win for regenerative medicine, as legislators passed a bill allotting nearly $50 million over 10 years for regenerative medicine research, clinical translation and commercialization efforts.

Some of that research funding has now been awarded to Bruce Walcheck, Ph.D., professor in the University of Minnesota Department of Veterinary and Biomedical Sciences, whose proposal was one of six funded out of 90 applications. Bruce is the principal investigator on a new $500,000 grant for research on engineering human pluripotent stem cells to generate enhanced natural killer cells for cancer therapy. The ultimate goal: treating cancer using the patients immune system.

A unique scientific and medical resource, pluripotent stem cells are self-replicating and have the potential to differentiate into almost any cell in the body. They are an important starting cell population for engineering enhanced immune cells for cell-based therapies that have the potential to cure various types of cancer. The investigative team will generate natural killer cells, which are part of the human bodys first line of defense against cancer cells and virus-infected cells.

Our long-term goal is to engineer human-induced pluripotent stem cells to generate a renewable source of super natural killer cells to enhance current therapies and the patients immune system in killing cancer cells, Walcheckexplained. Natural killer cells play a vital role in the fight against cancer. In contrast to other lymphocytes, natural killer cells kill malignant cells without being restricted to specific antigens or requiring considerable expansion. Standardized natural killer cell-based immunotherapies can therefore be more readily administered to patients.

However, during their expansion for transfer into patients and in the tumor environment, natural killer cells can down-regulate key receptors, resulting in their dysfunction. Our objective is to genetically modify human-induced pluripotent stem cells to derive natural killer cells that maintain their expression of key receptors for enhanced anticancer activity.

The other members of the multidisciplinary investigative team are Dan Kaufman, M.D., Ph.D., professor, Medical School (coinvestigator); Jianming Wu, D.V.M., Ph.D., associate professor, College of Veterinary Medicine (coinvestigator); Jeffrey Miller, M.D., Ph.D., professor, Medical School (collaborator); Melissa Geller, M.D., associate professor and gynecologic oncologist, Medical School (collaborator); and Paul Haluska, M.D., Ph.D., associate professor of oncology, Mayo Clinic (collaborator).

Members of the Masonic Cancer Center, University of Minnesota, are involved in this research.

Read more:
Minnesota invests in regenerative medicine - Health Talk

Posted in Minnesota Stem Cells | Comments Off on Minnesota invests in regenerative medicine – Health Talk

Page 1,644«..1020..1,6431,6441,6451,646..1,6501,660..»